Taysha Gene Therapies said its lead Rett syndrome candidate, TSHA-102, remains well tolerated, with no severe treatment-related serious adverse events reported

Taysha Gene Therapies said its lead Rett syndrome candidate, TSHA-102, remains well tolerated, with no severe treatment-related serious adverse events reported to date. The update came with Q3 earnings and keeps focus on the gene therapy program’s clinical progress.